Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.

Genetic variation in genes involved in hormones, inflammation and energetic factors and breast cancer risk in an admixed population. Carcinogenesis (2012) 1.40

GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer. Breast Cancer Res (2013) 0.95

Gemcitabine resistance in breast cancer cells regulated by PI3K/AKT-mediated cellular proliferation exerts negative feedback via the MEK/MAPK and mTOR pathways. Onco Targets Ther (2014) 0.86

Breast carcinoma cells in primary tumors and effusions have different gene array profiles. J Oncol (2009) 0.83

The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity. BMC Cancer (2011) 0.79

The role of the chemokine receptor XCR1 in breast cancer cells. Breast Cancer (Dove Med Press) (2017) 0.75

Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity. Oxid Med Cell Longev (2017) 0.75

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08

The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24

SHIP represses the generation of alternatively activated macrophages. Immunity (2005) 7.41

Metastatic behavior of breast cancer subtypes. J Clin Oncol (2010) 6.17

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med (2010) 6.04

Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst (2005) 5.65

Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol (2010) 5.44

Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med (2015) 4.94

Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol (2012) 4.14

Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol (2007) 3.58

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2012) 3.07

Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol (2010) 2.53

Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther (2006) 2.40

Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol (2006) 2.38

Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol (2008) 2.38

Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol (2003) 2.34

Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res (2008) 2.20

Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst (2007) 2.03

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol (2009) 1.99

Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res (2007) 1.88

Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem (2005) 1.86

The liposomal formulation of doxorubicin. Methods Enzymol (2005) 1.62

Impact of routine pathology review on treatment for node-negative breast cancer. J Clin Oncol (2012) 1.59

Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta (2007) 1.56

Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res (2012) 1.50

Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267. Cancer Biol Ther (2011) 1.47

Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer (2005) 1.47

Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol (2007) 1.45

Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model. Cancer Biol Ther (2004) 1.39

A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. Cancer Res (2011) 1.33

Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res (2006) 1.31

Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res (2008) 1.29

Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res (2008) 1.25

Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res (2004) 1.24

Predictors of supervised exercise adherence during breast cancer chemotherapy. Med Sci Sports Exerc (2008) 1.23

In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med (2004) 1.20

Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. J Natl Cancer Inst (2013) 1.18

Barriers to supervised exercise training in a randomized controlled trial of breast cancer patients receiving chemotherapy. Ann Behav Med (2008) 1.16

Moderators of the effects of exercise training in breast cancer patients receiving chemotherapy: a randomized controlled trial. Cancer (2008) 1.15

Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene (2005) 1.14

The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol (2004) 1.11

Predictors of follow-up exercise behavior 6 months after a randomized trial of exercise training during breast cancer chemotherapy. Breast Cancer Res Treat (2008) 1.10

QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Res (2009) 1.09

Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med (2006) 1.08

Six-month follow-up of patient-rated outcomes in a randomized controlled trial of exercise training during breast cancer chemotherapy. Cancer Epidemiol Biomarkers Prev (2007) 1.07

Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol (2005) 1.06

Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res (2004) 1.05

Treatment beyond progression: is it moving from belief to evidence? Oncologist (2010) 1.05

Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. PLoS One (2013) 1.04

Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol (2006) 1.03

The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo. J Pharm Sci (2010) 1.02

Histone demethylase Jumonji D3 (JMJD3) as a tumor suppressor by regulating p53 protein nuclear stabilization. PLoS One (2012) 1.02

Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta (2002) 1.00

Leishmania major abrogates gamma interferon-induced gene expression in human macrophages from a global perspective. Infect Immun (2007) 1.00

Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol Cancer Ther (2007) 1.00

Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin. Clin Cancer Res (2008) 0.99

Adjuvant targeted therapy in early breast cancer. Cancer (2009) 0.99

Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta (2006) 0.99

Effects of exercise during adjuvant chemotherapy on breast cancer outcomes. Med Sci Sports Exerc (2014) 0.99

Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. Arch Pathol Lab Med (2008) 0.99

Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther (2006) 0.99

The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities. Health Qual Life Outcomes (2011) 0.98

Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Mol Cancer Ther (2008) 0.98

Comparison of bifunctional chelates for (64)Cu antibody imaging. Eur J Nucl Med Mol Imaging (2010) 0.98

Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model. Am J Clin Oncol (2008) 0.98

TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer. Clin Breast Cancer (2009) 0.96

Differentiation of vascular smooth muscle cells from local precursors during embryonic and adult arteriogenesis requires Notch signaling. Proc Natl Acad Sci U S A (2012) 0.95

pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. Biochim Biophys Acta (2004) 0.95

Targeting quiescent tumor cells via oxygen and IGF-I supplementation. Cancer Res (2011) 0.93

Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture. Cancer Res (2004) 0.93

Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. Biochim Biophys Acta (2002) 0.92

Effects of exercise dose and type on sleep quality in breast cancer patients receiving chemotherapy: a multicenter randomized trial. Breast Cancer Res Treat (2014) 0.92

Hemoglobin and aerobic fitness changes with supervised exercise training in breast cancer patients receiving chemotherapy. Cancer Epidemiol Biomarkers Prev (2010) 0.91

Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine (2003) 0.91

In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm (2006) 0.91

First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin Cancer Res (2007) 0.91

Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. Clin Cancer Res (2008) 0.90

Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine. BMC Cancer (2011) 0.90

Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J Pharmacol Exp Ther (2002) 0.90

Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials. Vaccine (2005) 0.90

RGD conjugates of the H2dedpa scaffold: synthesis, labeling and imaging with 68Ga. Nucl Med Biol (2012) 0.89

HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab. Arch Pathol Lab Med (2008) 0.89

Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica (2010) 0.89

HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Mol Cancer Res (2004) 0.89